14 - 16 May, 2019 | Hotel Novotel Amsterdam Schiphol Airport, Amsterdam, Netherlands

Conference Day Two

9:10 am - 9:45 am Broadening Patient Reach in Emerging Markets

Francisco Ballester - President, Latin America, Sandoz
  • Understand the opportunity for growth in emerging markets 
  • Explore the challenges and opportunities of utilizing both government and out-of-pocket strategies to maximize patient access and commercialization in emerging markets 
  • Explore models with peer-proven success to expand patient reach, with case studies 
img

Francisco Ballester

President, Latin America
Sandoz

9:45 am - 10:20 am Case Study: Manufacturing Biosimilars for Checkpoint Inhibitors

Louis Boon - Chief Scientific Officer, Polpharma
  • Ensure biosimilarity and high productivity with upstream process modulation 
  • Utilise novel SPOT™ and SLIM™ technologies on the CHOBC® platform to reduce COGs
  • Combine biosimilar checkpoint inhibitors to reduce healthcare expenditures 
img

Louis Boon

Chief Scientific Officer
Polpharma

10:20 am - 10:50 am Networking Coffee Break

10:50 am - 11:25 am Overcome the Bottleneck Limiting Patient Access in the UK Home Care System

Kalveer Flora - Specialist Pharmacist Rheumatology and Biosimilars, London North West Healthcare NHS Trust
  • Ensure your post market success and maximize patient access in the UK by navigating the HomeCare system  
  • Consider the business implications of the failure to deliver biosimilars  to patients in the UK
  • Optimise your supply chain by exploring methods to guarantee the delivery of biosimilars to patients in the UK
img

Kalveer Flora

Specialist Pharmacist Rheumatology and Biosimilars
London North West Healthcare NHS Trust

11:25 am - 12:00 pm Exploring Key Strategies to Avoid Completion

Andreas Herrmann - Chief Executive Officer, Valerius Biopharma AG
  • Explore the competitive landscape and learn to differentiate yourself by improving formulation and discuss other defining factors
  • Design effective methods for successful market access
  • Benchmark your own practice with an SME with a case study for low competition
img

Andreas Herrmann

Chief Executive Officer
Valerius Biopharma AG

12:00 pm - 1:00 pm Networking Lunch

  • Undertake a Healthcare Fiscal overview, exploring the medicine funding landscape for biosimilars and the New NHS CQUINS on Biosimilars and its implementation  
  • Hear how payers are aligning biosimilars with innovative parent brands to streamline patient care settings
  • Consider what the differential payer value drivers are for switching from parent brand to biosimilar, compared to biosimilar to biosimilar
  • Bridge the uncertainty gap between payers &pharma – the shifting paradigm
img

Omar Ali

Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICE
University of Portsmouth

  • Explore the contentious idea that real world evidence is an unnecessary undertaking in the commercialisation of biosimilars
  • Consider the pros and cons of incremental registration for multiple indications
  • Hear the views of a sponsoring company, pharmacist, and payer
img

Sue Caleo-Naeyaert

Global Head Government Affairs, Policy and Pharmaceconomics
Fresenius Kabi SwissBioSim

img

Kalveer Flora

Specialist Pharmacist Rheumatology and Biosimilars
London North West Healthcare NHS Trust

img

Omar Ali

Advisor on value Based Pricing, US Embassy, Lecturer Value Based Pricing & Outcomes Based Innovative Contracting, University of Portsmouth & Former Member Adoption & Impact Panel, NICE
University of Portsmouth

2:20 pm - 2:50 pm Networking Coffee Break

  • Consider how a patient may feel powerless when being forced/ encouraged to switch to a biosimilar 
  • Discuss how the science behind a biosimilar, with respect to complexity, may add to patients skepticism and the importance to educate patients about their safety and efficacy to allay their fears 
  • Explore the commercial significance of switching, with respect to the necessity to switch established patients between brands to allow hospitals to avoid only using biosimilars for new treatment starts 



img

Sue Caleo-Naeyaert

Global Head Government Affairs, Policy and Pharmaceconomics
Fresenius Kabi SwissBioSim

  • Confront trials by engaging with a physician to explore how manufacturers and regulators hope to maintain the trust of the public in a relatively novel class of medicines, faced with such potential for future variability, mistrust and misinformation
  • Explore how the risks of  extrapolation of indications can be minimised and the significance of this practice for the biosimilar industry
  • Bring your own challenges to the forefront of the industry and discuss how to tackle prescriber objections 
img

Michael Muenzberg

Biosimilars Consultant
Biosimilars Consulting CH

img

Dr Paul Cornes

Oncologist
NHS